Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

• The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients. • LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients. • LA was not associated with thrombotic complications. • The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12...

Descripción completa

Detalles Bibliográficos
Autores principales: Siguret, Virginie, Voicu, Sebastian, Neuwirth, Marie, Delrue, Maxime, Gayat, Etienne, Stépanian, Alain, Mégarbane, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Letter to the Editors-in-Chief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342042/
https://www.ncbi.nlm.nih.gov/pubmed/32663703
http://dx.doi.org/10.1016/j.thromres.2020.07.016
_version_ 1783555350433103872
author Siguret, Virginie
Voicu, Sebastian
Neuwirth, Marie
Delrue, Maxime
Gayat, Etienne
Stépanian, Alain
Mégarbane, Bruno
author_facet Siguret, Virginie
Voicu, Sebastian
Neuwirth, Marie
Delrue, Maxime
Gayat, Etienne
Stépanian, Alain
Mégarbane, Bruno
author_sort Siguret, Virginie
collection PubMed
description • The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients. • LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients. • LA was not associated with thrombotic complications. • The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12%.
format Online
Article
Text
id pubmed-7342042
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73420422020-07-09 Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Siguret, Virginie Voicu, Sebastian Neuwirth, Marie Delrue, Maxime Gayat, Etienne Stépanian, Alain Mégarbane, Bruno Thromb Res Letter to the Editors-in-Chief • The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients. • LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients. • LA was not associated with thrombotic complications. • The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12%. Elsevier Ltd. 2020-11 2020-07-08 /pmc/articles/PMC7342042/ /pubmed/32663703 http://dx.doi.org/10.1016/j.thromres.2020.07.016 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editors-in-Chief
Siguret, Virginie
Voicu, Sebastian
Neuwirth, Marie
Delrue, Maxime
Gayat, Etienne
Stépanian, Alain
Mégarbane, Bruno
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
title Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
title_full Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
title_fullStr Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
title_full_unstemmed Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
title_short Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
title_sort are antiphospholipid antibodies associated with thrombotic complications in critically ill covid-19 patients?
topic Letter to the Editors-in-Chief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342042/
https://www.ncbi.nlm.nih.gov/pubmed/32663703
http://dx.doi.org/10.1016/j.thromres.2020.07.016
work_keys_str_mv AT siguretvirginie areantiphospholipidantibodiesassociatedwiththromboticcomplicationsincriticallyillcovid19patients
AT voicusebastian areantiphospholipidantibodiesassociatedwiththromboticcomplicationsincriticallyillcovid19patients
AT neuwirthmarie areantiphospholipidantibodiesassociatedwiththromboticcomplicationsincriticallyillcovid19patients
AT delruemaxime areantiphospholipidantibodiesassociatedwiththromboticcomplicationsincriticallyillcovid19patients
AT gayatetienne areantiphospholipidantibodiesassociatedwiththromboticcomplicationsincriticallyillcovid19patients
AT stepanianalain areantiphospholipidantibodiesassociatedwiththromboticcomplicationsincriticallyillcovid19patients
AT megarbanebruno areantiphospholipidantibodiesassociatedwiththromboticcomplicationsincriticallyillcovid19patients

Ejemplares similares